Active Recombinant Human EPO protein, hFc-tagged

• Cat.No.: EPO-200H
• Product Overview: Recombinant Human EPO protein(NP_000790.2)(Met1-Arg193), fused with hFc tag, was expressed in HEK293.

Specification

• Species: Human
• Source: HEK293
• Tag: Fc
• Protein Length: 1-193 a.a.
• Form: Lyophilized from sterile PBS, pH 7.4.Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.
• Bio-activity: 1. Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED50 for this effect is 2.0-8.0 ng/mL.2.Immobilized Recombinant Human EPO Receptor / EPOR Protein (ECD, His Tag) at 2 μg/mL (100 μL/well) can bind Recombinant Human Erythropoietin / EPO Protein (Fc Tag), the EC50 is 5-15 ng/mL.
• Molecular Mass: The recombinant human EPO consists 404 amino acids and predicts a molecular mass of 45.1 kDa.
• Proteinlength: Met1-Arg193
• Endotoxin: < 1.0 EU per μg protein as determined by the LAL method.
• Purity: > 95 % as determined by SDS-PAGE.
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: EPO erythropoietin [ Homo sapiens ]
• Official Symbol: EPO
• Synonyms: EPO; erythropoietin; EP; epoetin; MVCD2; MGC138142
• Gene ID: 2056
• mRNA Refseq: NM_000799
• Protein Refseq: NP_000790
• MIM: 133170
• UniProt ID: P01588

Citation

Dual Delivery of EPO and BMP2 from a Novel Modular Poly-?-Caprolactone Construct to Increase the Bone Formation in Prefabricated Bone Flaps

Journal: Tissue Engineering. Part C, Methods    PubMed ID: 25809081    Data: 2015/9/1

Authors: Janki Jayesh Patel, Jane E. Modes, Scott J. Hollister

Article Snippet:BMP2, bone morphogenetic protein-2; EPO, erythropoietin.BMP2, bone morphogenetic protein-2; EPO, erythropoietin.. EPO binding to PCL scaffolds One hundred micrograms of EPO (Creative BioMart) was reconstituted in 1 mL sterile Dulbecco's phosphate-buffered saline (DPBS) to result in 12,000 IU/mL (0.1 mg/mL).. The stock solution was further diluted to the desired concentrations in DPBS.The stock solution was further diluted to the desired concentrations in DPBS.

Modular scaffold assembly. BMP2 was adsorbed onto the inner scaffold module and EPO was adsorbed onto the outer scaffold module. The two scaffolds were then assembled. BMP2, bone morphogenetic protein-2; EPO, erythropoietin.

Protein release profiles. (A) BMP2 cumulative release profile. After 7 days, 0.0311±0.0053 μg BMP2 was released into phosphate-buffered saline at 37°C. (B) BMP2 release. A small burst release occurred in the first 2 days, followed by sustained release. (C) EPO cumulative release profile. After 7 days, 119.2±29.4 IU of the 139.6±28.6 IU that was bound was released. (D) EPO released over 7 days with a small burst release in the first 2 days. (n=3/group).

Adsorbed EPO bioactivity. HUVECs seeded on the PCL disc exposed to EPO showed increased levels of proliferation. n=4; *p<0.05. HUVEC, human umbilical vein endothelial cells; PCL, poly-?-caprolactone.